Completed PHASE2 INTERVENTIONAL NCT00329121
Study to Determine the Safety of Two Applications of PEP005 Topical Gel to Cutaneous Squamous Cell Carcinoma In Situ
Multi-centre, Open-label Study to Determine the Safety and Efficacy of PEP005 0.05% Topical Gel in Patients With Cutaneous Squamous Cell Carcinoma In Situ (SCCIS, Bowen's Disease)
Sponsor: Peplin
Conditions
Carcinoma, Squamous Cell
Interventions
PEP005
Updated 1 time since 2024 Last updated: Jan 16, 2015 Started: May 31, 2006 Primary completion: Dec 31, 2006 Completion: Dec 31, 2006
This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.
This PHASE2 trial investigates Carcinoma, Squamous Cell and is currently completed. Peplin leads this study, which shows 1 recorded version since 2006 — indicating limited longitudinal coverage. As an oncology study, it adds to the longitudinal record of treatment development for this indication.
Status Flow
Change History
1 version recorded Completed — PHASE2
[monthly]
Eligibility Summary
No eligibility information available.
Contact Information
Sponsor contact:
- Peplin
Data source: Peplin
For direct contact, visit the study record on ClinicalTrials.gov .